Evidence map›Paper›PMID 37298546›Full record

ArticleInternational journal of molecular sciences2023

Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy.

Yuki Iizuka, Yoshiyuki Manabe, Kazuhiro Ooe, Atsushi Toyoshima, Xiaojie Yin, Hiromitsu Haba, Kazuya Kabayama, Koichi Fukase

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuki IizukaDepartment of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan.
Yoshiyuki ManabeDepartment of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan.ORCID 0000-0002-5515-3923
Kazuhiro OoeRadioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan.
Atsushi ToyoshimaDivision of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan.
Xiaojie YinRIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan.
Hiromitsu HabaRIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan.
Kazuya KabayamaDepartment of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan.
Koichi FukaseDepartment of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan.ORCID 0000-0001-8844-0710

Funding

Japan Agency for Medical Research and Development 20ek0109444h0001Japan Agency for Medical Research and Development 20fk0210079h0001Japan Science and Technology Agency JPMJCR20R3Japan Science and Technology Agency JPMJFR211ZJapan Society for the Promotion of Science 20H05675Japan Society for the Promotion of Science 20K05727Japan Society for the Promotion of Science 21H05074
6 · The paper itself

Abstract

Targeted alpha therapy (TAT) has garnered significant interest as an innovative cancer therapy. Owing to their high energy and short range, achieving selective α-particle accumulation in target tumor cells is crucial for obtaining high potency without adverse effects. To meet this demand, we fabricated an innovative radiolabeled antibody, specifically designed to selectively deliver

Indexed as

NeoplasmsRadioisotopesCell NucleusDrug Delivery SystemsHumansRadioisotopesdrug delivery system (DDS)imagingnuclear localization signal (NLS)radiolabeled antibodytargeted alpha therapy (TAT)α-ray

Identifiers

PMID37298546
PMCPMC10253442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.